Neuphoria Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 17, 2026
NEUP$2.76-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Cons olidated Balance Sheets (Unaudited)
| December 31, | June 30, | |
|---|---|---|
| 2025 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $22,170,414 | $14,210,745 |
| Accounts receivable, non-trade | 1,109,908 | 11,948 |
| Restricted cash | 79,647 | 77,945 |
| Prepaid insurance expense | 26,954 | 740,193 |
| Total current assets | 23,386,923 | 15,040,831 |
| Property and equipment, net | - | 2,771 |
| Intangible assets, net | 4,473,426 | 4,804,791 |
| Operating lease right-of-use assets | - | 102,612 |
| Goodwill | 8,737,953 | 8,638,609 |
| Total assets | $36,598,302 | $28,589,614 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $520,709 | $1,154,369 |
| Accrued expenses and other current liabilities | 2,065,599 | 2,950,077 |
| Operating lease liability | - | 116,314 |
| Total current liabilities | 2,586,308 | 4,220,760 |
| Contingent consideration | 1,172,859 | 1,169,675 |
| Deferred tax liability | 425,527 | 495,113 |
| Accompanying warrants liability | 2,712,784 | 3,701,492 |
| Total liabilities | 6,897,478 | 9,587,040 |
| Commitments and contingencies (Note 17) | ||
| Shareholders’ equity: | ||
| Common stock, $0.00001 par value, 5,377,329 and 1,978,460 shares issued and outstanding at December 31, 2025 and June 30, 2025, respectively | 54 | 19 |
| Additional paid-in capital, net of subscription receivable | 218,315,150 | 200,194,324 |
| Accumulated other comprehensive loss, net of tax | (2,225,265) | (2,845,066) |
| Accumulated deficit | (186,389,115) | (178,346,703) |
| Total shareholders’ equity | 29,700,824 | 19,002,574 |
| Total liabilities and shareholders’ equity | $36,598,302 | $28,589,614 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.